

CITATION REPORT

List of articles citing

Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

DOI: 10.1002/ana.24471

Annals of Neurology, 2015, 78, 501-14.

Source: <https://exaly.com/paper-pdf/60782387/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Dimethyl fumarate/ethyl fumarate. <i>Reactions Weekly</i> , 2015 , 1575, 89-89	0	
39	Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. <i>Therapeutic Advances in Neurological Disorders</i> , 2015 , 8, 274-93	6.6	29
38	PML: The Dark Side of Immunotherapy in Multiple Sclerosis. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 799-801	13.2	27
37	Steering through complexity: management approaches in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016 , 29, 263-71	7.1	10
36	Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. <i>British Journal of Dermatology</i> , 2016 , 175, 250-62	4	32
35	Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. <i>Journal of Neurology</i> , 2016 , 263, 1511-7	5.5	10
34	Fingolimod-associated PML in a patient with prior immunosuppression. <i>Neurology</i> , 2016 , 86, 1843-5	6.5	41
33	Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. <i>Current Infectious Disease Reports</i> , 2016 , 18, 33	3.9	10
32	Diagnostic delay in progressive multifocal leukoencephalopathy. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 386-91	5.3	17
31	Multiple sclerosis: Dimethyl fumarate is coming of age. <i>Nature Reviews Neurology</i> , 2016 , 12, 436-7	15	4
30	Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. <i>Journal of Neurology</i> , 2016 , 263, 2004-21	5.5	45
29	Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016 , 3, e211	9.1	58
28	Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2016 , 22, 464-71	3.9	10
27	More on PML in Patients Treated with Dimethyl Fumarate. Author reply. <i>New England Journal of Medicine</i> , 2016 , 374, 295	59.2	8
26	[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. <i>Der Nervenarzt</i> , 2016 , 87, 645-59	0.5	11
25	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016 , 12, 217-33	15	148
24	Progressive multi-focal leukoencephalopathy'-driven from rarity to clinical mainstream by iatrogenic immunodeficiency. <i>Clinical and Experimental Immunology</i> , 2017 , 188, 342-352	6.2	18

23	Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients. <i>Journal of Immunology</i> , 2017 , 198, 3069-3080	5.3	99
22	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. <i>Journal of Neurology</i> , 2017 , 264, 1155-1164	5.5	63
21	Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. <i>British Journal of Radiology</i> , 2017 , 90, 20160721	3.4	22
20	Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1176-1178	5	2
19	Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No. <i>Revue Neurologique</i> , 2017 , 173, 614-615	3	
18	Progressive multifocal leukoencephalopathy and psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 271-272	4	
17	Demyelination during anti-tumour necrosis factor therapy for psoriasis. <i>Clinical and Experimental Dermatology</i> , 2018 , 43, 577-578	1.8	4
16	T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. <i>Immunobiology</i> , 2018 , 223, 508-517	3.4	19
15	Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. <i>Clinical and Experimental Dermatology</i> , 2018 , 43, 72-75	1.8	4
14	Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 51-57	4	14
13	A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study. <i>Internal Medicine</i> , 2018 , 57, 2727-2734	1.1	4
12	Remitting long-standing major depression in a multiple sclerosis patient with several concurrent conditions. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 2545-2550	3.1	3
11	Japanese guidelines for dimethyl fumarate. <i>Clinical and Experimental Neuroimmunology</i> , 2018 , 9, 235-243	3.4	2
10	Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 893-905	4.6	4
9	The spectrum of progressive multifocal leukoencephalopathy: a practical approach. <i>European Journal of Neurology</i> , 2019 , 26, 566-e41	6	22
8	Oral Therapies for Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	14
7	Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. <i>Journal of Neurology</i> , 2020 , 267, 125-131	5.5	18
6	Progressive multifokale Leukenzephalopathie Ein Update. <i>DGNeurologie</i> , 2020 , 3, 437-450	0.2	

5	Clinical Significance of Infection on Psoriasis Severity. <i>Journal of Interferon and Cytokine Research</i> , 2021 , 41, 44-51	3.5	1
4	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 281-317	4.6	19
3	Central Nervous System Infections Complicating Immunosuppression and Transplantation. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018 , 24, 1370-1396	3	5
2	Psoriasis and Guillain-Barré Syndrome: Incidental or Associated?. <i>Archives of Rheumatology</i> , 2017 , 32, 273-274	0.9	1
1	A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors.. <i>Journal of Central Nervous System Disease</i> , 2021 , 13, 11795735211037798	4.4	1